 Today I have the pleasure of speaking with Dr. Horst Serb of Intel Genics Technologies. How are you today? I'm very good. Thank you. I'd like to start by congratulating you with the licensing deal you just made with Tidalafil. That's significant. Can you tell our audience what that is? Actually, I can. We entered into a binding term sheet with Lilly for their dosing patent for Tidalafil. So Dr. Serb, I understand through the great mind that this took a shockingly small, minimal amount of time for you to make this deal. I mean, usually deals with large companies like Eli Lilly take years of negotiations. Can you talk to us a little bit about this? I'm not really at liberty to disclose any details. Let me just say that the parties were working against a timeline that in this case worked very much in our favor and that required us to keep the time period to achieve this very short. So obviously there are many large corporations and pharmaceutical companies that are watching you presently if you're making deals in this kind of rapid period. Can you tell us what we should expect as shareholders maybe in the next couple of months and next couple quarters other than I think people should be watching Intel Genics if you're making deals with these large pharmaceutical companies so quickly? Yeah. I mean, really the significance of this deal lies in the fact that it has completely cleared any litigation path way for Intel Genics towards entering into licensing. So in other words, previously potential licensees had to be concerned about litigation that they might be facing after entering into a licensing deal. No more litigation threat for whoever our licensing partner is going to be. And that of course makes the pathway towards launch and commercialization of the product extremely easy. And when you're talking about the commercialization of the product, you're talking about the burst of limb technology. Is that correct? Yes. Yes, that is correct. Well, we're certainly looking forward to more outstanding news from Intel Genics. Thank you so much for joining us today. Thank you very much.